Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Apogee Therapeutics, Inc. (APGE) since 2023 are shown in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Apogee Therapeutics, Inc.. Table 2 shows the detailed insider transactions. This company's CIK number is 1974640.
Total stock buying since 2023: $80,738,692.
Total stock sales since 2023: $12,954,617.
Total stock option exercises since 2023: $422,336.
| Insider Buying | Insider Sales | Option Exercises | ||||
|---|---|---|---|---|---|---|
| Year | Shares | Value | Shares | Value | Shares | Value |
| 2025 | 0 | $0 | 61,785 | $2,537,490 | 16,660 | $380,846 |
| 2024 | 20,000 | $988,700 | 215,530 | $10,417,127 | 1,815 | $41,490 |
| 2023 | 4,691,176 | $79,749,992 | 0 | $0 | 0 | $0 |
| Trading Period | Insider Buying | Insider Sales | Option Exercises | |||
|---|---|---|---|---|---|---|
| year-month | Shares | Value | Shares | Value | Shares | Value |
| 2025-07 | 0 | $0 | 10,090 | $459,165 | 7,365 | $168,363 |
| 2025-05 | 0 | $0 | 2,725 | $97,418 | 0 | $0 |
| 2025-04 | 0 | $0 | 3,860 | $141,766 | 0 | $0 |
| 2025-03 | 0 | $0 | 11,590 | $351,463 | 0 | $0 |
| 2025-02 | 0 | $0 | 18,520 | $751,928 | 795 | $18,173 |
| 2025-01 | 0 | $0 | 15,000 | $735,750 | 8,500 | $194,310 |
| 2024-12 | 20,000 | $988,700 | 26,205 | $1,233,598 | 1,815 | $41,490 |
| 2024-11 | 0 | $0 | 21,665 | $1,289,459 | 0 | $0 |
| 2024-10 | 0 | $0 | 46,665 | $2,632,839 | 0 | $0 |
| 2024-09 | 0 | $0 | 46,665 | $2,228,620 | 0 | $0 |
| 2024-08 | 0 | $0 | 53,335 | $2,247,550 | 0 | $0 |
| 2024-07 | 0 | $0 | 20,995 | $785,061 | 0 | $0 |
| 2023-07 | 4,691,176 | $79,749,992 | 0 | $0 | 0 | $0 |
| Trade Date | Insider Name | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2025-07-02 | Dambkowski Carl (Chief Medical Officer) | Sale | 10,090 | 45.51 | 459,165 |
| 2025-07-02 | Dambkowski Carl (Chief Medical Officer) | Option Ex | 7,365 | 22.86 | 168,363 |
| 2025-05-07 | Dambkowski Carl (Chief Medical Officer) | Sale | 2,725 | 35.75 | 97,418 |
| 2025-04-02 | Dambkowski Carl (Chief Medical Officer) | Sale | 3,860 | 36.73 | 141,766 |
| 2025-03-05 | Dambkowski Carl (Chief Medical Officer) | Sale | 1,590 | 30.48 | 48,463 |
| 2025-03-05 | Henderson Michael Thomas (Chief Executive Officer) | Sale | 10,000 | 30.30 | 303,000 |
| 2025-02-05 | Dambkowski Carl (Chief Medical Officer) | Sale | 3,520 | 40.69 | 143,228 |
| 2025-02-05 | Dambkowski Carl (Chief Medical Officer) | Option Ex | 795 | 22.86 | 18,173 |
| 2025-02-05 | Henderson Michael Thomas (Chief Executive Officer) | Sale | 15,000 | 40.58 | 608,700 |
| 2025-01-31 | Henderson Michael Thomas (Chief Executive Officer) | Option Ex | 8,500 | 22.86 | 194,310 |
| 2025-01-08 | Henderson Michael Thomas (Chief Executive Officer) | Sale | 15,000 | 49.05 | 735,750 |
| 2024-12-12 | Mckenna Mark C. | Buy | 20,000 | 49.44 | 988,700 |
| 2024-12-11 | Dambkowski Carl (Chief Medical Officer) | Sale | 4,540 | 49.31 | 223,867 |
| 2024-12-11 | Dambkowski Carl (Chief Medical Officer) | Option Ex | 1,815 | 22.86 | 41,490 |
| 2024-12-04 | Dambkowski Carl (Chief Medical Officer) | Sale | 6,665 | 46.07 | 307,056 |
| 2024-12-04 | Henderson Michael Thomas (Chief Executive Officer) | Sale | 15,000 | 46.84 | 702,675 |
| 2024-11-06 | Dambkowski Carl (Chief Medical Officer) | Sale | 6,665 | 59.44 | 396,134 |
| 2024-11-06 | Henderson Michael Thomas (Chief Executive Officer) | Sale | 15,000 | 59.55 | 893,325 |
| 2024-10-02 | Dambkowski Carl (Chief Medical Officer) | Sale | 6,665 | 56.51 | 376,639 |
| 2024-10-02 | Henderson Michael Thomas (Chief Executive Officer) | Sale | 40,000 | 56.41 | 2,256,200 |
| 2024-09-04 | Dambkowski Carl (Chief Medical Officer) | Sale | 6,665 | 47.77 | 318,420 |
| 2024-09-04 | Henderson Michael Thomas (Chief Executive Officer) | Sale | 40,000 | 47.76 | 1,910,200 |
| 2024-08-23 | Henderson Jane (Chief Financial Officer) | Sale | 6,000 | 48.26 | 289,560 |
| 2024-08-07 | Dambkowski Carl (Chief Medical Officer) | Sale | 7,335 | 41.37 | 303,470 |
| 2024-08-07 | Henderson Michael Thomas (Chief Executive Officer) | Sale | 40,000 | 41.36 | 1,654,520 |
| 2024-07-05 | Henderson Michael Thomas (Chief Executive Officer) | Sale | 15,000 | 37.26 | 558,900 |
| 2024-07-03 | Dambkowski Carl (Chief Medical Officer) | Sale | 5,995 | 37.73 | 226,161 |
| 2023-07-13 | Shah Nimish P | Buy | 1,750,000 | 17.00 | 29,750,000 |
| 2023-07-13 | Harwin Peter Evan | Buy | 2,941,176 | 17.00 | 49,999,992 |
Insider trading activities including stock purchases, stock sales, and option exercises of APGE listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Apogee Therapeutics, Inc. (symbol APGE, CIK number 1974640) see the Securities and Exchange Commission (SEC) website.